Navigation Links
NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure

SANTA CLARA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that it has completed a restructure of the going-forward terms of its December 27, 2007 financing. As a result of this agreement, the investors in the transaction have exercised a portion of their existing warrants, adding $2.8 million in cash to NewCardio's balance sheet. This will extend the Company's cash reserves to past the expected revenue ramp, based on current and projected cash burns. The agreement also results in a simplified capital structure that includes a restriction on transfer of certain of the Company's securities held by those investors that can extend through September 30, 2009.

    Key terms of the agreement:

    --  The initial investors, affiliates of Vision Capital Advisors, and
        Platinum Partners have agreed to an early exercise of a portion of
        their warrants, adding $2.8 million to NewCardio's cash reserves.
    --  NewCardio's balance sheet strengthened by resulting reclassification
        of investment from debt and Preferred Shares to equity under US GAAP.
        The September 30, 2007 warrant liability of $21.7 million in
        liabilities and $2.0 million in Preferred Shares Subject to Redemption
        will now be classified in Equity.
    --  The cash from the warrant exercise and the above reclassifications, in
        aggregate, resulted in a net increase to equity on the Company's
        balance sheet of $26.5 million.
    --  The investors agreed to "lock up" certain of their securities for a
        period that can extend to September 30, 2009. This agreement removes
        all existing overhangs from the 2007 investment.
    --  All preferences associated with the 2007 transaction, including
        anti-dilution protection and rights impacting management decisions,
        have been removed. The Company's capital structure now contains only
        common stock, preferred "B" stock with no voting rights and the "A"
        warrants, which have a $1.14 strike price, expire in four years
        (12/27/12) and have been amended to remove preferences.

    The following pro forma balance sheet is based on historical financial
statements giving the effect of the transaction as if occurred on September
30, 2008:

                                 NewCardio, Inc.
                             Pro forma Balance Sheet
                                September 30, 2008

                                                Pro forma
                              As filed          Adjustments          Pro forma
    Current assets:
    Cash and investments    $3,329,443 (1)       $2,800,000         $6,129,443
    Other current assets        29,329                    -             29,329
      Total current assets   3,358,772            2,800,000          6,158,772
    Property and equipment      90,471                    -             90,471
    Other assets                12,600                    -             12,600
    Total assets            $3,461,843           $2,800,000         $6,261,843
    Current liabilities     $1,024,023                   $-         $1,024,023
    Warrant liability       21,653,301 (1),(2)  (21,653,301)                 -
      Total liabilities     22,677,324          (21,653,301)         1,024,023
    Preferred shares
     subject to redemption   2,020,226 (3)       (2,020,226)                 -
    Equity                 (21,235,707)(4)       26,473,527          5,237,820
      Total liabilities and
      stockholders' equity  $3,461,843           $2,800,000         $6,261,843

     (1) To record receipt of cash for exercise of warrants
     (2) To adjust for the reclassification of remaining warrants to equity
     (3) To Adjust for the cancellation of preferred shares subject to
         redemption and issuance of series B preferred stock
     (4) As described above

Election of Jess Jones, MD as Director

The Company's Board of Directors has elected Jess Jones, MD, the Director of Healthcare Investing of Vision Capital Advisors, LLC the investment manager of its largest shareholder, to fill a vacancy on the Board.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "This agreement enhances our cash position, and extends our cash reserves to past our expected revenue ramp. In addition, the agreement significantly simplifies our capital structure, removes significant overhang in the stock and eliminates the initial investors' preferences that were in place. The restructuring demonstrates the confidence our initial investors have in NewCardio. We are pleased to have completed this favorable transaction and welcome Dr. Jones to our Board of Directors."

Dr. Jones spent the last two years at Vision Capital Advisors analyzing investment opportunities in the biotech, pharmaceutical, medical technology, and medical services fields. Previously, he spent one year as a research associate at Columbia University in the Department of Neurosurgery. In this role, he was awarded a Medical Student Research Fellowship from the American Heart Association. Prior to that, he spent three years at the University of Utah in the Department of Radiology, also as a research associate. He earned both an MBA and his MD from Columbia University, and a BA from the University of Utah.

"NewCardio possesses novel technology that has the potential to add value to each of the more than 325 million electrocardiographs performed each year," commented Dr. Jones. "As an investor, we are impressed with the team the Company has assembled to develop and commercialize this technology across the entire range of cardiology and healthcare. We are further pleased with the pace at which the Company has progressed. Accordingly, Vision Capital Advisors was pleased to assist the Company with the restructure of the original terms of the financing, demonstrating Vision's long-term commitment to NewCardio. I am excited to join the Company's Board of Directors to assist the Company in the successful execution of its business plan."

About Vision Capital Advisors, LLC

Vision Capital Advisors, LLC is an SEC-registered investment adviser. Vision Capital Advisors, LLC specializes in making value-oriented investments in fundamentally strong small public companies in the US and abroad.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NewCardio Announces New Client Services Team
2. VaxGen Restructures Following Termination of Proposed Merger
3. Pharmos Restructures Operations in Israel
4. Clear Catheter Systems Completes $600-Million Financing, Opens Cleveland Office
5. Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
6. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
7. AGA Medical Receives European CE Mark Approval for AMPLATZER(R) Cardiac Plug
8. diaDexus Receives CE Mark Certification for the PLAC(R) Test
9. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
10. President George W. Bush Receives International Medal of PEACE That Coincides With PEPFAR Milestone on World Aids Day:
11. Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
Post Your Comments:
(Date:11/28/2015)... ... 28, 2015 , ... StatRad , a leading provider ... and Claude Hooton to its board of directors. The announcement comes as the ... Annual Meeting and continues to strategically transform its focus from being a teleradiology ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 15th by ... handling security in light of the recent terrorist attacks in Paris, other cities are ... an attack from reaching U.S. soil. Especially around special events that may be high-profile ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... filthy the toilets were," said an inventor from Hillside, N.J. "Many people catch ... seat cover so that individuals will always be protected from germs." , He ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology: